Tag
The I-SPY2.2 trial evaluated rilvegostomig combined with trastuzumab-deruxtecan in high-risk ERBB2-negative early breast cancer, showing promising pathologic complete response rates in immune-positive tumors while reducing exposure to anthr
The DESTINY-Breast08 phase 1b study demonstrates that trastuzumab deruxtecan (T-DXd) combined with chemotherapy, AKT inhibitors, or endocrine therapy is manageable and clinically active in HER2-low metastatic breast cancer, offering new pat
This review analyzes the Phase 1b DESTINY-Lung03 trial results, highlighting the robust efficacy of trastuzumab deruxtecan monotherapy in HER2-overexpressing NSCLC and the prohibitive toxicity encountered when combined with durvalumab and p
The DESTINY-Breast05 trial demonstrates that Trastuzumab Deruxtecan significantly improves invasive disease-free survival compared to Trastuzumab Emtansine in patients with residual HER2-positive early breast cancer, establishing a new pote
The FDA has approved trastuzumab deruxtecan with pertuzumab as first-line therapy for unresectable or metastatic HER2‑positive breast cancer after DESTINY‑Breast09 showed a large PFS benefit versus standard THP; safety and maintenance strat
DESTINY‑Breast04 shows trastuzumab deruxtecan (T‑DXd) significantly improves progression‑free and overall survival vs physician’s choice chemotherapy in HER2‑low metastatic breast cancer, with manageable safety and preserved patient‑reporte
Trastuzumab deruxtecan combined with pertuzumab significantly improves progression-free survival over standard therapy in first-line HER2-positive metastatic breast cancer, offering enhanced response duration with manageable safety.
This study uses real-world data to compare the effectiveness and safety of trastuzumab deruxtecan versus trastuzumab emtansine and tucatinib in HER2-positive metastatic breast cancer, confirming their clinical value.
The PRO-DUCE randomized trial demonstrates that electronic symptom and vital sign monitoring during trastuzumab deruxtecan therapy can preserve quality of life in ERBB2-positive metastatic breast cancer patients, with notable improvements i
Trastuzumab deruxtecan (T-DXd) gains FDA approval for HR-positive, HER2-low and HER2-ultralow unresectable or metastatic breast cancer after endocrine therapy progression, offering significant progression-free survival benefits over chemoth
Phase 3 data show trastuzumab deruxtecan significantly improves survival over ramucirumab plus paclitaxel in HER2-positive metastatic gastric cancer, with manageable safety, supported by real-world evidence from Japan.
